TrialFrontiers in immunology2021

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells.

Fabio Guolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.